The ShortCut™ Study Protocol

NCT ID: NCT04952909

Last Updated: 2025-02-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-21

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Clinical Study to Demonstrate the Safety and Effectiveness of the ShortCut™ device for splitting bioprosthetic aortic valve leaflets in patients who are presented for a valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) procedure for an approved ViV indication, and who are at risk for TAVR-induced coronary artery ostium obstruction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ShortCut™

Group Type EXPERIMENTAL

ShortCut™

Intervention Type DEVICE

Splitting bioprosthetic aortic valve leaflets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ShortCut™

Splitting bioprosthetic aortic valve leaflets

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is planned to undergo a percutaneous valve-in-valve procedure for an approved valve-in-valve indication due to a failed bioprosthetic valve.
* Written informed consent to participate in the study obtained from the subject or subject's legal representative, according to local regulations, prior to initiation of any study mandated procedure.

Exclusion Criteria

* An excessive aortic valve leaflet Calcium morphology or anatomy not suitable for the use of the ShortCut™ device.
* Coronary, carotid or vertebral artery disease that, in the opinion of the local Heart Team, should be treated; or treatment of such disease ≤ 1 month prior to index procedure.
* Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) ≤ 6 months prior to index procedure, or severe neurological disability.
* Myocardial infarction (MI) ≤ 6 weeks prior to index procedure.
* Hemodynamic or respiratory instability.
* Left ventricle ejection fraction \< 30%.
* Ongoing severe infection, sepsis or endocarditis.
* Renal insufficiency
* Need for emergency surgery for any reason.
* Life expectancy is less than 1 year.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pi-cardia

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tucson Medical Center

Tucson, Arizona, United States

Site Status

Smidt Heart Institute Cedars-Sinai Medical

Los Angeles, California, United States

Site Status

Kaiser Permanente - San Francisco Medical Center

San Francisco, California, United States

Site Status

Los Robles Regional Medical Center

Thousand Oaks, California, United States

Site Status

Medstar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Advocate Christ Medical Center

Oak Lawn, Illinois, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Morristown Medical Center

Morristown, New Jersey, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Carolinas Medical Center / Atrium Health

Charlotte, North Carolina, United States

Site Status

UPMC Pinnacle

Wormleysburg, Pennsylvania, United States

Site Status

Baylor Scott & White, The Heart Hospital Plano

Plano, Texas, United States

Site Status

Intermountain Medical Center

Murray, Utah, United States

Site Status

CHU de Bordeaux (Bordeaux University Hospital)

Bordeaux, , France

Site Status

Institute Mutualiste Montsouris

Paris, , France

Site Status

Clinique Pasteur

Toulouse, , France

Site Status

German Heart Institute Berlin

Berlin, , Germany

Site Status

University Hospital Hamburg

Hamburg, , Germany

Site Status

Leipzig Heart Institute

Leipzig, , Germany

Site Status

Sha'are Tzedek Medical Center

Jerusalem, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

Royal Sussex County Hospital

Brighton, , United Kingdom

Site Status

Leeds General Infirmary

Leeds, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States France Germany Israel United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S01-CLN-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.